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Epstein-Barr virus (EBV) is a human gammaherpesvirus associated with several
malignancies. We reported previously that an EBV lytic gene product BRRF2 is involved
in the maturation of progeny virus. To analyze the domain(s) needed for efficient
production of progeny, we prepared a series of deletion mutants and found two
functional domains in the N- and C-terminal regions by complementation assays.
Immunofluorescence analyses revealed that BRRF2 lacking the C-terminal region
demonstrated aberrant localization in both the nucleus and cytoplasm, whereas
wild-type BRRF2 was localized predominantly in the cytoplasm. We also confirmed
that wild-type BRRF2 co-localized with Rab5, an endosomal marker, at least partly.
Additionally, serine 511 of BRRF2 was phosphorylated during lytic infection; however,
a mutant in which the serine was substituted with alanine still augmented the yield as
efficiently as did wild-type BRRF2. These results showed that the C-terminal region of
BRRF2 is involved in the predominant localization of BRRF2 to the cytoplasm and in the
efficient production of infectious virus.
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INTRODUCTION
The Epstein-Barr virus (EBV) is a human gammaherpesvirus that is present in most of the world’s
population. EBV has DNA genome of approximately 170–180 kb that encodes more than 80 genes.
Mature virus particles are transmitted via saliva, and infection occurs by invasion of the oral cavity
and pharynx to establish infection in epithelial cells and B cells. In general, primary infection is
asymptomatic; however, its infection causes infectious mononucleosis in a small minority of adults.
Besides, EBV is associated with several proliferative disorders of lymphocytes and epithelials,
including Burkitt lymphoma, Hodgkin lymphoma, chronic active EBV infection (CAEBV), and
T/NK lymphoma. (Young et al., 2016).
Epstein-Barr virus can establish two types of infections: latent and lytic infections (Murata and
Tsurumi, 2014). In the latent state, the viral genomic DNA exists in the nucleus in a chromatinized
state (episome), in which it expresses only a limited number of viral latent genes (Lieberman, 2013).
In the lytic state, all lytic genes of EBV are expressed and progeny virus particles are produced
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(Hammerschmidt and Sugden, 2013). Switching from the latent
to lytic state is called reactivation. Reactivation can be triggered
by exogenous expression of a viral immediate-early (IE) gene,
BZLF1 (also called Zta, Z, ZEBRA, and EB1). BZLF1, in
cooperation with another IE gene BRLF1 (also known as
Rta and R), can efficiently elicit the expression of early (E)
genes involved in viral DNA synthesis and late (L) gene
induction. Viral DNA genomes are amplified at a discrete site
in the host nucleus called replication compartments (Tsurumi
et al., 2005). Several E genes (BcRF1, BVLF1, BGLF3, BFRF2,
BDLF4, and BDLF3.5) form a complex in the nucleus and
induce transcription of L genes in a TATT sequence (non-
canonical TATA sequence)-dependent manner (Watanabe et al.,
2015a; Djavadian et al., 2016; Gruffat et al., 2016). L genes
encode capsid, tegument, and envelope proteins. Capsid proteins
are assembled in the nucleus, and newly synthesized EBV
genomic DNA is packaged into capsids (Murata, 2014). After
nucleocapsid formation, the virus undergoes an envelopment, de-
envelopment, and re-envelopment pathway common to alpha-
herpesvirus (Mettenleiter et al., 2006; Johnson and Baines,
2011). In this model, after DNA packaging in the nucleus,
the nucleocapsids bud into the inner nuclear membrane to
form an enveloped particle (primary envelopment). When these
particles fuse with the outer nuclear membrane, the envelope
is lost, and nucleocapsids are released into the cytoplasm (de-
envelopment). In the cytoplasm, nucleocapsids bud into the
cytoplasmic membrane structure—likely via the trans-Golgi
network (TGN) or endosomes—along with various tegument
proteins (secondary envelopment). The virions are then released
into the extracellular space by fusion of the organelle with the
plasma membrane.
The BRRF2 protein of EBV is conserved among the
gammaherpesvirus group, which include ORF48 of Kaposi’s
sarcoma-associated herpesvirus (KSHV) and murine
gammaherpesvirus 68 (MHV-68). We demonstrated previously
that BRRF2 is expressed during the L phase and is localized
in the cytoplasm (Watanabe et al., 2015b). Whereas BRRF2
is important for the production of progeny viruses, it is not
required for viral gene expression or viral DNA replication
(Watanabe et al., 2015b). Similarly, the ORF48 gene of MHV-
68 appears to play a crucial role in progeny production
(Qi et al., 2015). Mass-spectrometry analysis showed that
BRRF2 is detectable as a phosphorylated tegument protein
(Johannsen et al., 2004), but its phosphorylation is not
mediated by the viral protein kinase BGLF4 (Watanabe
et al., 2015b).
In this study, we generated mutant BRRF2 expression
vectors to examine the domain(s) of the tegument protein
important for progeny virus production. Our complementation
assays revealed that the N- and C-terminal domains are
required for efficient virus production. Interestingly, deletion
of the C-terminal domain of BRRF2, which includes several
clusters of acidic amino acids, caused aberrant intracellular
localization. Furthermore, we revealed that serine 511 of
BRRF2 is phosphorylated in cells, although substitution of
the serine for alanine did not influence the complementation
efficiency.
MATERIALS AND METHODS
Cell Culture and Reagents
HEK293 (Delecluse et al., 1998) and HeLa (Kawashima et al.,
2013) cells were maintained in Dulbecco’s modified Eagle
medium (DMEM, Gibco BRL) supplemented with 10% fetal
bovine serum (FBS). HEK293 cells infected with EBV BRRF2
knockout virus (Watanabe et al., 2015b) were cultured with
DMEM containing 150 µg/ml hygromycin B. Akata EBV
negative cells (Akata(-)), B95-8, and AGS-EBV cells (Katsumura
et al., 2009) were cultured in RPMI 1640 medium containing 10%
FBS.
Rabbit antibodies against BZLF1 and BALF2 were used as
reported previously (Murata et al., 2009; Sugimoto et al., 2013).
Mouse anti-FLAG antibody was purchased from Sigma-Aldrich,
and rabbit anti-Giantin antibody was from Abcam. Rabbit
Anti-tubulin, -Calnexin, and -Rab5 antibodies were purchased
from Cell Signaling Technology. Mouse anti-BMRF1 antibody
was purchased from Novocastra. Horseradish peroxidase-linked
goat antibodies to mouse or rabbit IgG were from Amersham
Biosciences.
Plasmid Construction
Two expression vectors, pcDNABZLF1 and pcDNAFLAGBRRF2,
were reported previously (Watanabe et al., 2015b). All mutant
vectors with deletions or substitutions in BRRF2 were generated
by inverse PCR using Flag-tagged wild type BRRF2 expression
plasmid as a template. To generate the deletion mutants shown in
Figures 1A and 2A, we used the following primers: for11-96: 5′-
TGTCTGGGTGTTATTCCAGG-3′ (forward), and 5′-CATGA
ATTCCTTGTCATCGT-3′ (reverse), for 197–180: 5′-CAT
GTGCAGCTTGCATACGA-3′ (forward), and 5′-TAAGTTG
TGGGCCGTGGTTA-3′ (reverse), for 1181-272: 5′-TTTTA
TCTCCCGACGACAGG-3′ (forward), and 5′-ACCACGTAAA
GCCACAAGCT-3′ (reverse), for 1273-341: 5′-TTAACGAG
CAGAGGGAATGA-3′ (forward), and 5′-GTGATTATCCGA
ATTTCGGA-3′ (reverse), for 1342-441: 5′-GACCTTGAA
GAGGAAGAGGA-3′ (forward), and 5′-CTGAGAGCATGTC
TGCTGGG-3′ (reverse), for 1442-537: 5′-TAACTCGAGCAT
GCATCTAG-3′ (forward), and 5′-ACCAGACAGAGATGCTA
CTG-3′ (reverse). The C-terminal deletion mutants were
generated using the following primers: for 1442-470: 5′-GAGG
CTCAGGACGCAAATCT-3′ (forward), and 5′- ACCAGACA
GAGATGCTACTG-3′ (reverse), for 1471-498: 5′-GAGGATGG
GGAATTTTCAGA-3′ (forward), and 5′-AAGCCAGGCCTCA
AATTCCT-3′ (reverse), for 1499-537: 5′-GACCATGAAGG
GGATGAGG-3′ (forward), and 5′-CGAACCATCCTCGTCCT
CAT-3’ (reverse), for 1512-537: 5′-TAACTCGAGCATGCA
TCTAG-3′ (forward), and 5′-GCTGTCAGACAGATCCA-3′
(reverse). The mutants harboring the serine-to-alanine sub-
stitution were prepared in the same fashion using the following
primers: for S498A: 5′-GCGGAGGATGGGGAATTTTC-3′
(forward), and 5′- ACCATCCTCGTCCTCATCAC-3′ (reverse),
for S504A: 5′- GCAGACCTGGATCTGTCTGA-3′ (forward),
and 5′- AAATTCCCCATCCTCCGAAC-3′ (reverse), for
S509A: 5′-GACAGCGACCATGAAGGGGA-3′ (forward), and
5′- AGCCAGATCCAGGTCTGAAA-3′ (reverse), for S511A:
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5′- GCCGACCATGAAGGGGATGA-3′ (forward), and 5′-
GTCAGACAGATCCAGGTCTG-3′ (reverse).
Complementation Assay
To induce lytic replication in HEK293 cells carrying EBV
BAC clones, cells were transfected with pcDNABZLF1 using
the Neon transfection system (Invitrogen). At 72 h after
transfection, cells and culture medium were collected, followed
by freezing and thawing. After centrifugation at 13,000 rpm,
the supernatants were mixed to Akata(-) cells for 3 h at room
temperature with rotation, and the medium was replaced with
fresh medium. At 48 h post-infection, cells were fixed with
1% formaldehyde, washed with PBS, and suspended in PBS.
GFP-positive cells were counted using the FACSCalibur G5
system (Becton-Dickinson), according to the manufacturer’s
instructions.
Immunofluorescence Staining
HeLa cells were transfected with the indicated expression vectors
using lipofectamine 2000 reagent (Invitrogen) and fixed with
70% ethanol. Cells were permeabilized using 0.1% Triton-
X100, blocked using 10% normal goat serum (Funakoshi), and
stained with anti-FLAG mouse antibody (Sigma), followed by
washing and treatment with secondary antibody (Alexa 555
anti-mouse IgG, Invitrogen). AGS-EBV cells were transfected
with BZLF1 and FLAG-BRRF2 using lipofectamine 2000
reagent. The cells were fixed with 70% ethanol on glass
slides, permeabilized, and blocked. After staining with anti-
FLAG mouse antibody and anti-BALF2 rabbit antibody, cells
were reacted with secondary antibodies (Alexa Fluor 555
anti-mouse and anti-rabbit IgG, Invitrogen). B95-8 cells were
transfected using the Neon transfection system (Invitrogen)
and stained with mouse anti-BMRF1 antibody directly labeled
with Alexa Fluor 488 using Zenon Alexa IgG labeling reagent
(Invitrogen). After washing with PBS, cells were mounted using
ProLong Diamond Antifade Mountant with DAPI (Invitrogen).
Confocal microscopy (LSM880, Zeiss) was used to analyze the
samples.
Immunoblotting
For conventional SDS-PAGE, HEK293 cells carrying each BAC
clone were transfected with the BZLF1 and BRRF2 mutant
vectors using the Neon transfection system to induce lytic
infection. After 2 days, cells were washed with PBS and lysed
using sample buffer for SDS-PAGE. Electrophoresis, transfer, and
staining were carried out as described previously (Narita et al.,
2015).
Separation and Detection of
Phosphoprotein
HEK293 cells latently infected with BRRF2-knockout EBV
were transfected with pcDNABZLF1 together with expression
vector for wild-type or mutant FLAG-tagged BRRF2. After
one day, cells were lysed in phosphatase buffer (Santa
Cruz). Lysed samples were reacted with or without Lambda
phosphatase (Santa Cruz). Protein samples were separated on
a 7.5% Phos-tag gel (Wako chemicals). After electrophoresis,
the Phos-tag gel was washed with transfer buffer containing
EDTA to remove zinc ions from the gel, according to the
manufacturer’s instructions, followed by immunoblotting as
specified above.
RESULTS
Functional Domains of BRRF2
To identify the functional domain(s) of BRRF2 involved in virus
production, we determined whether BRRF2 mutants lacking
various amino acid regions could complement the decreased
viral titer caused by disruption of the BRRF2 gene. We prepared
BRRF2 mutant vectors, each lacking ∼90 amino acids in various
regions, as depicted in Figure 1A. These FLAG-tagged deletion
mutant vectors were transfected into HEK293 cells latently
infected with the BRRF2-knockout EBV BAC clone established
previously (Watanabe et al., 2015b). Wild-type BRRF2 increased
the virus yield of the BRRF2-knockout virus by two- or three-
fold (Figure 1B) (Watanabe et al., 2015b). Likewise, mutants
lacking the central regions of BRRF2 (1181–272, 1273–341,
and 1342–441) successfully restored the impaired viral titer
(Figure 1B). However, BRRF2 mutants lacking residues 1–180
at the N-terminus (11–96 and 197–180) and 442–537 at the
C-terminus (1442–537) failed to restore the reduced virus yield
(Figure 1B). This result suggested that EBV BRRF2 has two
important domains in both the N- and C-terminal regions
(residues 1–180 and 442–537) required for efficient production
of virus progeny.
Cytoplasmic Localization of BRRF2
Requires the C-Terminal Region
We demonstrated previously that BRRF2 is localized
predominantly in the cytoplasm of infected and transfected
cells (Watanabe et al., 2015b). To investigate whether BRRF2
deletions alter the intracellular localization of the protein, we
used immunofluorescence assays to observe the distribution of
the mutant proteins. HeLa cells were transfected with vectors
harboring the deletion mutants (shown in Figure 1A), stained
with anti-FLAG antibody, and observed by confocal microscopy.
Although BRRF2 lacking the N-terminal or central regions
was localized in the cytoplasm in a manner similar to that of
wild-type BRRF2, C-terminally truncated BRRF2 (1442–537)
was found not only in the cytoplasm but also in the nucleus
(Figure 1C). This result indicates that the C-terminal region
of BRRF2 is required for its predominant localization in the
cytoplasm, at least when produced in the absence of other viral
proteins.
To analyze BRRF2 localization in the context of infection,
we stained B95-8 and AGS-EBV cells after lytic induction
(Figure 1D). The BMRF1 protein was also stained to monitor
the lytic induction. Regardless of the cell type or presence
of truncated BRRF2, BMRF1 protein was clearly localized
in the nucleus as expected (Figure 1D). Whereas wild-
type BRRF2 was detected mainly in the cytoplasm, the
C-terminally truncated mutant (1442–537) was distributed in
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FIGURE 1 | Functional domains of BRRF2. (A) Schematic diagram of Epstein-Barr virus (EBV) BRRF2 mutant vectors. Deletion mutants were prepared as
described in Section “Materials and Methods”, using the N-terminally FLAG-tagged wild-type BRRF2 expression plasmid as a template. (B) Complementation
assays. HEK293 cells latently infected with the BRRF2-knockout EBV BAC clone were co-transfected with BZLF1 and expression vectors harboring wild-type or
deletion mutants of BRRF2. After 3 days, the supernatants were co-cultured with Akata(-) cells, and after 2 days, FACS analysis was performed to measure the viral
titer by determining the GFP-positive ratio. Protein levels were examined by immunoblotting. (C) Intracellular localization of wild-type or deletion mutants of BRRF2.
HeLa cells were transfected with vectors containing FLAG-tagged wild-type BRRF2 or the BRRF2 deletion mutants. One day after transfection, cells were fixed,
permeabilized and stained with ant-FLAG (BRRF2, red) antibody and DAPI (blue) and analyzed by using confocal laser microscopy. (D) Intracellular localization of
BRRF2 in EBV-positive cells during lytic infection. B95-8 (upper panels) or AGS-EBV (lower panels) cells were transfected with BZLF1 and BRRF2 vectors by
electroporation or lipofection, respectively. After 2 days, cells were harvested and stained with anti-FLAG (BRRF2, red), BMRF1, or BALF2 (green) antibodies and
DAPI (blue) and analyzed by confocal laser microscopy. The white bar indicates 10 µm.
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FIGURE 2 | The C-terminal region of BRRF2 regulates its cytoplasmic localization (A) Schematic diagram of EBV BRRF2 mutant vectors. Acidic cluster
motifs are indicated with shadowing. (B) Complementation assays. HEK293 cells carrying the BRRF2-knockout EBV BAC clone were transfected with BZLF1 and
the indicated BRRF2 vectors. Virus titer was determined as in Figure 1B. Protein levels were examined by immunoblotting. (C) Intracellular localization of wild-type
or deletion mutants of BRRF2. HeLa cells were transfected with vectors containing FLAG-tagged wild-type BRRF2 or the BRRF2 mutants. Cells were stained with
ant-FLAG (BRRF2, red) antibody and DAPI (blue) and analyzed by using confocal laser microscopy. The white bar indicates 10 µm.
the nucleus and cytoplasm (Figure 1D). This result indicated
that the BRRF2 C-terminal region is important for its
predominant localization in the cytoplasm, even in the context
of infection.
Mutants Containing a Narrow Set of
BRRF2 Deletions
Interestingly, residues 442–537 contain three stretches of acidic
amino acid clusters, as shown in Figure 1A and 2A. As several
herpesvirus gene products, such as EBV BBLF1 (Chiu et al.,
2012), retain acidic amino acid clusters crucial for localization
in the cytoplasm (including the Golgi apparatus), we speculated
that these acidic residues in BRRF2 might also play a role in
cytoplasmic localization.
To narrow down the C-terminal residues of BRRF2 important
for efficient progeny production and cytoplasmic distribution,
we further constructed four additional deletion mutant vectors
between residues 442 and 537 (1442–470, 1471–498, 1499–
537, and 1512–537), as shown in Figure 2A. Wild-type BRRF2
successfully augmented the viral titer, but the 1442–537 mutant
failed to do so (Figure 2B). However, all four deletion mutants
of BRRF2 increased the yield almost as efficiently as did wild-
type BRRF2 (Figure 2B). In addition, all four mutant proteins
were localized in the cytoplasm, similar to the wild-type protein
(Figure 2C). These results suggest the presence of redundant
acidic amino acids in the BRRF2 protein.
Phosphorylation of BRRF2 Serine 511
During the Lytic Cycle
Previous reports have shown that the tegument protein BRRF2
is phosphorylated in infected cells (Johannsen et al., 2004;
Watanabe et al., 2015b). To identify the phosphorylation site
of BRRF2, we used the phos-tag electrophoresis system, in
which phosphate residues are bound by phos-tag molecules, thus
retarding the mobility of phosphoproteins during electrophoresis
(Kinoshita-Kikuta et al., 2007). Phosphoproteins treated with
phosphatase migrate through the gel faster than those without
phosphatase treatment.
We first analyzed the phosphorylation state of BRRF2 mutants
lacking various amino acid regions (see Figure 1A) with or
without phosphatase treatment (Figure 3A). HEK293 cells
expressing EBV BRRF2 lacking residues 442–537 migrated at
the same speed in the phos-tag gel regardless of phosphatase
treatment (Figure 3A, 1442–537). In contrast, wild-type or
other deletion mutant BRRF2 proteins (11–96,197–180,1181–
272, 1273–341, and 1342–441) migrated faster when de-
phosphorylated (Figure 3A). Thus, residues 442–537 contain
phosphorylated amino acid.
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FIGURE 3 | Phosphorylation of BRRF2 at serine 511. (A) Phosphorylation of BRRF2 at its C-terminus (residues 442–537). HEK293 cells carrying the
BRRF2-knockout EBV BAC clone were transfected with BZLF1 and wild-type or BRRF2 deletion mutants (shown in Figure 1A) and harvested on day 2 with or
without lambda phosphatase treatment. Protein samples were electrophoresed on a Phos-tag gel or by conventional SDS-PAGE for detection of BRRF2 and tubulin
by immunoblotting. (B) Phosphorylation of BRRF2 within residues 499–511. Mutants containing a narrow set of BRRF2 deletions (shown in Figure 2A) were
transfected, harvested, and blotted as in (A). (C) Schematic diagram of EBV BRRF2 mutant vectors. Acidic cluster motifs are indicated with shadowing. Serine
residues substituted with alanine residues were indicated with black background. (D) Phosphorylation of BRRF2 at serine 511. Mutants containing alanine
substitution of serines 498, 504, 509, 511 (shown in Figure 3C) were transfected, harvested, and blotted as in (A). (E) Phosphorylation of serine 511 did not
influence the ability of BRRF2 to improve viral yield. HEK293 cells carrying the BRRF2-knockout EBV BAC clone were transfected with BZLF1 and the indicated
BRRF2 vectors. Virus titer was determined as in Figure 1B. Protein levels were examined by immunoblotting. Intracellular localization of wild-type or S511A mutant
of BRRF2 was examined by immunofluorescence in HeLa cells.
Next, we examined the deletion mutants (1442–470, 1471–
498, 1499–537, and 1512–537) to determine which specific
region is phosphorylated (see Figure 2A). BRRF2 1512–
537 migrated faster when treated with phosphatase, whereas
the mobility of BRRF2 1499–537 did not change in the
presence or absence of phosphatase (Figure 3B), indicating that
phosphorylated amino acid is between residues 499 and 511.
We thus created four mutants with alanine substitutions
at each of the four serine residues in this region as shown
in Figure 3C and evaluated whether these mutants were
phosphorylated (Figure 3D). The results showed that BRRF2
S511A protein migrated similarly regardless of phosphatase
treatment (Figure 3D), indicating that serine 511 undergoes
phosphorylation.
We then subjected the BRRF2 S511A mutant to a
complementation assay and found that this mutant restored the
production of progeny as efficiently as did wild-type BRRF2
(Figure 3E left panels). In addition, BRRF2 S511A protein
showed a similar localization pattern as that observed with wild-
type BRRF2 (Figure 3E right panels). These results suggested
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FIGURE 4 | Co-staining of BRRF2 with organelle markers. HeLa cells
were transfected with the vector for FLAG-tagged wild-type BRRF2. Cells
were stained with ant-FLAG (BRRF2, red), Giantin (upper panels, green),
Calnexin (middle panels, green), and Rab5 (lower panels, green) antibodies
and DAPI (blue) and analyzed by using confocal laser microscopy. The white
bar indicates 10 µm.
that BRRF2 serine 511 is phosphorylated during lytic infection;
however, this phosphorylation is not essential for efficient
production of viral progeny.
Detailed Analysis of Intercellular
Localization of BRRF2
To clarify the localization of BRRF2 in the cytoplasm, we
transfected HeLa cells with wild-type BRRF2 and co-stained with
markers of cytoplasmic organelles (Figure 4). The pattern of
Giantin, which is known to localize in the Golgi apparatus, was
different from that of BRRF2 although a part of BRRF2 protein
might colocalize (Figure 4 upper panels). The Calnexin resides
in endoplasmic reticulum (ER). It might colocalize with BRRF2
protein, albeit only partly (Figure 4 middle panels). Interestingly,
localization of BRRF2 matched at least partially with Rab5,
which is a marker of endosomes, especially of early endosome
(Figure 4 lower panels). Therefore, unlike BBLF1 (Chiu et al.,
2012), BRRF2 likely localizes more efficiently to endosomes, than
Golgi apparatus and ER.
DISCUSSION
We investigated the domains of the BRRF2 protein required for
efficient production of progeny by analyzing deletion mutants
of BRRF2. We found that the amino acids in the N-terminal
(1–180) and C-terminal (442–537) regions of BRRF2 are crucial
for efficient EBV multiplication (Figure 1). Interestingly, the
C-terminal portion of BRRF2, which contains three stretches of
acidic residues, appears to be crucial for appropriate cytoplasmic
localization of the protein and optimal production of virus
particles (Figure 1). A similar acidic cluster motif was reported
to play an essential role in the cytoplasmic trafficking of Furin,
a cellular protease that cleaves many proteins in the secretory
pathway (Thomas, 2002). Furin has two serine residues (773
and 775) within its acidic motif that are phosphorylated by
casein kinase 2 (CK2). When phosphorylated, the acidic cluster
of Furin consolidates binding to phospho-furin acidic cluster
sorting protein-1 (PACS-1), which then directs Furin to the
TGN (Wan et al., 1998). After this finding, many cellular
and viral proteins were found to have acidic clusters (and in
some cases, phosphorylation motifs within the acidic cluster)
that are crucial for cytoplasmic localization. For example, HIV
Nef binds to PACS-1 through its acidic cluster, resulting in
relocalization of cell surface MHC class I molecules to the TGN
(Piguet et al., 2000). Many herpesvirus tegument proteins and
glycoproteins contain acidic amino acid clusters. HSV VP22
retains an acidic cluster that is essential for TGN localization
and incorporation into virions (O’Regan et al., 2010). HSV
UL11 and its homologs, HCMV UL99 and EBV BBLF1, are
localized to the TGN via their acidic clusters (Loomis et al.,
2001; Jones and Lee, 2004; Chiu et al., 2012). The acidic cluster
motifs of HCMV gB interact with PACS-1, and this interaction
facilitates its localization to the TGN (Crump et al., 2003).
KSHV tegument protein ORF45 also harbors an acidic patch,
through which ORF45 interacts with another tegument protein
ORF36 (Avey et al., 2016). Similar to Furin, EBV BRRF2 has a
phosphorylation motif in one of the acidic clusters (Figure 3).
However, in our study, substitution of serine 511 with an alanine
did not alter the intracellular localization, indicating that the
phosphorylation-dependent mechanism may not be applicable
to BRRF2. KSHV ORF48, a homolog of EBV BRRF2, contains
conserved acidic cluster motifs, which may contribute to its
cytoplasmic localization in a manner similar to that of EBV
BRRF2.
In addition to the acidic clusters and CK2-phosphorylated
residues in the clusters, a dileucine-based motif (LL or
replacement of the second leucine with isoleucine, valine, or
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methionine) and a tyrosine-based motif (YXXF, where X is any
amino acid and F is an amino acid with a bulky hydrophobic
side chain) have been reported to control localization in the TGN
of at least some proteins (Gu et al., 2001). Typically, the LL-
based motif is surrounded by or adjacent to acidic clusters. EBV
BRRF2 contains four LL, one LI, three LV, and one LM motifs,
but none of the possible LL motifs are within or around the acidic
clusters; all possible LL motifs are actually in the N-terminal half
of the protein. We identified a potential tyrosine-based motif
(Y150EIP) in the N-terminal portion of BRRF2. However, deletion
of the N-terminal region of BRRF2 had little or no effect on its
localization (Figure 1C), indicating that these residues probably
do not function as TGN-targeting motifs.
Although the mislocalization to the nucleus and little or no
improvement of viral yield by BRRF2 were observed in the case
of1442–537 mutant (Figure 1), the change in localization of the
protein may not necessarily be the direct cause of lower titer. To
further clarify the consequences, we need to test BRRF2 mutants
with smaller deletions. However, such effort was not successful
because the mutants with smaller deletions all acted like wild-type
BRRF2 (Figure 2).
Unlike other cellular or viral proteins bearing acidic cluster
motifs, we lastly showed that BRRF2 merged, to some
extent, with Rab5, an endosome marker. It is speculated that
presence of acidic clusters (the possible targeting motif for
TGN) in the BRRF2 protein still makes sense because TGN
and endosomes have intricate communications. Endosomal
distribution of a tegument protein BRRF2 suggests that the
secondary envelopment of EBV may take place at the endosome,
where viral nucleocapsids incorporate tegument proteins and
wear envelope.
In addition to the C-terminal region, N-terminal 180 residues
of BRRF2 were also involved in the restoration of viral yield,
without obviously affecting its localization (Figure 1). We
speculate that the N-terminal portion of BRRF2 protein may
interact with other viral tegument or capsid protein while the
C-terminal domain may aid cytoplasmic membrane targeting.
Such bipolar interaction might somehow promote efficient
tegumentation and/or secondary envelopment on the surface of
cytoplasmic membrane, such as TGN or endosome. Interestingly,
we hear that ORF48 of murine gammaherpesvirus-68 (homolog
of EBV BRRF2) may interact with a capsid protein (Dr. Ohno
(University of the Ryukyus), personal communication).
The molecular mechanisms by which BRRF2 potentiates the
production of EBV progeny remain unclear; however, our data
in this and previous reports (Watanabe et al., 2015b) suggest
that BRRF2 enhances secondary envelopment and efficient
tegumentation in the cytoplasm. Further studies on BRRF2 and
other tegument and envelope proteins are required to clarify EBV
tegumentation and secondary envelopment processes in greater
detail.
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